Other non-operating income
and (expense), net* (1,170) 8,922 (5,247) 8,542
Net loss $ (18,354) $ (16,228) $ (45,019) $ (38,853)
Basic and diluted net loss
per share: $ (0.30) $ (0.27) $ (0.73) $ (0.64)
Shares used in computing
basic and diluted net loss
per share 61,371 61,005 61,318 60,977
Condensed Consolidated Balance Sheet Data
At June 30, At December 31,
in thousands (unaudited)
Cash and investments** $ 49,433 $ 94,058
Total assets 110,617 156,208
Total liabilities 297,446 301,858
Total shareholders' equity (186,829) (145,650)
* Other non-operating expense for the three and six months ended June 30, 2008 principally reflect an unrealized loss resulting from the revaluation of the company's non-current auction rate security investments as of June 30, 2008.
** Cash and investments include cash equivalents, restricted cash equivalents, current and non-current investments.
Any statements contained in this presentation that relate to future
plans, events or performance are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results, and the timing of events, to
differ materially from those described in the forward-looking statements.
These risks and uncertainties include, among others, those relating to our
ability to obtain financing and to form collaborative relations
|SOURCE deCODE genetics|
Copyright©2008 PR Newswire.
All rights reserved